Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance.
Bone quality
Microarchitecture
Monoclonal gammopathy of undetermined significance
Osteoporosis
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
06
2018
accepted:
18
11
2018
revised:
12
11
2018
pubmed:
30
11
2018
medline:
20
8
2019
entrez:
30
11
2018
Statut:
ppublish
Résumé
Patients with monoclonal gammopathy of undetermined significance (MGUS) had abnormalities in volumetric BMD (vBMD), microarchitecture, and stiffness at both the radius and tibia by high-resolution peripheral quantitative CT compared to matched controls. This is the first report demonstrating that patients with MGUS have microarchitectural deficits at multiple skeletal sites. Fracture risk is elevated in patients with monoclonal gammopathy of undetermined significance (MGUS). However, the pathogenesis of bone disease in these patients is poorly understood. Prior work using high-resolution peripheral CT (HRpQCT) demonstrated abnormal microarchitecture at the radius, with predominantly cortical abnormalities. We hypothesized that patients with MGUS have abnormal microarchitecture at both radius and tibia compared to controls, reflecting global skeletal effects of the disease. This case-control study enrolled 36 subjects; patients with MGUS (n = 12) were matched 1:2 by age, sex, and race to controls (n = 24). Areal BMD (aBMD) was measured by DXA, vBMD, and microarchitecture by HRpQCT, and whole bone stiffness by finite element analysis. Serum was drawn for markers of bone metabolism and inflammation. By DXA, MGUS patients had lower aBMD at the lumbar spine, femoral neck, and 1/3 radius. Markers of bone metabolism and inflammation did not differ. By HRpQCT at the radius, MGUS patients had lower total, trabecular and cortical density, lower trabecular number, and greater trabecular separation and heterogeneity. At the tibia, MGUS patients had lower total and trabecular density, lower trabecular number, greater separation and heterogeneity, and lower whole bone stiffness. Patients with MGUS had lower vBMD, cortical, and trabecular abnormalities at the radius compared to matched controls. At the tibia, trabecular abnormalities predominated. These results suggest that in addition to previously described cortical deficits, deterioration of trabecular bone may contribute to a generalized skeletal fragility in patients with MGUS.
Identifiants
pubmed: 30488275
doi: 10.1007/s00198-018-4787-z
pii: 10.1007/s00198-018-4787-z
pmc: PMC10081445
mid: NIHMS1882006
doi:
Types de publication
Journal Article
Langues
eng
Pagination
629-635Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK084337
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR052665
Pays : United States
Organisme : NIAMS NIH HHS
ID : U01 AR055068
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : U01 AR055968
Références
J Bone Miner Res. 1999 Nov;14(11):1902-8
pubmed: 10571690
Br J Haematol. 2000 Apr;109(1):24-9
pubmed: 10848778
Intern Med J. 2001 Jul;31(5):272-8
pubmed: 11512598
Eur J Haematol. 2002 Jul;69(1):37-42
pubmed: 12270060
Blood. 2003 May 1;101(9):3568-73
pubmed: 12506012
J Bone Miner Res. 2004 Jan;19(1):25-30
pubmed: 14753733
Br J Haematol. 2004 Sep;126(5):686-9
pubmed: 15327520
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Br J Haematol. 2006 Sep;134(5):485-90
pubmed: 16848794
Br J Haematol. 2006 Oct;135(1):62-7
pubmed: 16925792
Eur J Haematol. 2008 Jun;80(6):490-4
pubmed: 18331598
Calcif Tissue Int. 2008 Jun;82(6):418-26
pubmed: 18528609
Acta Haematol. 2008;120(2):87-90
pubmed: 18852483
Eur J Haematol. 2009 Jan;82(1):31-8
pubmed: 19067746
Joint Bone Spine. 2010 Mar;77(2):120-4
pubmed: 20097594
Br J Haematol. 2010 Jul;150(1):28-38
pubmed: 20507313
J Bone Miner Res. 2010 Dec;25(12):2572-81
pubmed: 20564238
Blood. 2010 Oct 14;116(15):2651-5
pubmed: 20610813
J Clin Endocrinol Metab. 2011 Jul;96(7):2041-8
pubmed: 21508142
Blood. 2011 Dec 15;118(25):6529-34
pubmed: 22042700
J Clin Endocrinol Metab. 2012 Oct;97(10):E1918-26
pubmed: 22821893
Mayo Clin Proc. 2012 Nov;87(11):1071-9
pubmed: 22883742
J Bone Miner Res. 2013 May;28(5):1029-40
pubmed: 23225022
Leuk Lymphoma. 2014 Apr;55(4):911-9
pubmed: 23915193
Blood. 2014 Jan 30;123(5):647-9
pubmed: 24227822
Blood. 2014 Jan 30;123(5):603-4
pubmed: 24482495
J Bone Miner Res. 2014;29(5):1101-9
pubmed: 24877245
J Bone Miner Res. 2014 Dec;29(12):2529-33
pubmed: 25319751
Crit Rev Oncol Hematol. 2015 Oct;96(1):54-66
pubmed: 26044302
J Clin Invest. 2016 May 2;126(5):1759-72
pubmed: 27043283
Osteoporos Int. 2016 Oct;27(10):2955-66
pubmed: 27155883
Bone. 2017 Mar;96:29-37
pubmed: 27742498
J Bone Miner Metab. 2018 Jan;36(1):128-132
pubmed: 28243796
Blood. 1997 Nov 1;90(9):3743-50
pubmed: 9345061